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ELUCIDATING THE ROLE OF THE LONG NONCODING RNA, GTL2, IN 
RODENT MODELS OF CARDIAC DISEASE 
HEATHER HOOK 
ABSTRACT 
 
Recently, the discovery of noncoding RNAs (ncRNAs), such as long noncoding RNAs 
(lncRNAs) has altered the traditional view of gene regulation. Sequencing of genomes 
has brought to light the vast stretches of non-protein coding DNA regions that transcribe 
non-protein coding RNA. LncRNAs are multifunctional and extremely diverse. They can 
act as signals, decoys, scaffolds, guides, or enhancers. Several lncRNAs, such as Fendrr 
and Bvht, have been found to have important regulatory functions in cardiac disease and 
development. The Glt2-Dio3 locus, which is enriched in cardiac muscle, harbors two 
long intragenic RNAs, MEG3 and MEG8, and harbors one of the largest mammalian 
miRNA clusters. MEG3, which is termed Gtl2 in rat and mouse, contain 10 exons that are 
alternatively spliced and give rise to several variants. Gtl2 is conserved across human, rat, 
and mouse, which makes it an ideal candidate for research and a possible target for 
therapies. Based on the growing evidence for lncRNAs playing a role in cardiac muscle 
and our research on the Gtl2-Dio3 microRNAs (miRNAs), I focused on investigating the 
Gtl2 lncRNA in the heart. Antisense oligonucleotides (GapmeRs) were used to 
knockdown Gtl2 lncRNA expression levels in cultured, primary neonatal cardiomyocytes 
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in basal and hypertrophic conditions. Although Gtl2 was effectively knocked down in 
basal conditions I was unable to achieve efficient knockdown in hypertrophic 
cardiomyocytes induced by phenylephrine treatment. Consequently, I did not observe any 
modulation of hypertrophy as determined by changes in the expression of Nppa and 
Nppb, established markers of cardiomyocyte hypertrophy.. Next, I utilized short hairpin 
RNA (shRNA) to knockdown Gtl2 lncRNA expression levels and obtained robust 
knockdown. Lastly, I designed a cardiac tropic adeno-associated virus 9 (AAV9) 
encoding MEG3 DNA for in vivo overexpression experiments as well as an adenovirus 
encoding MEG3 for in vitro overexpression experiments. These reagents will provide 
valuable resources for dissecting the functions of the Gtl2 lncRNA. Studies investigating 
the roles of Gtl2 in the diseased heart my lead to the development of other potential 
therapies to treat cardiac disease.   
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CHAPTER 1: Introduction 
1.1 Introduction 
This thesis will focus on the roles of the Gene Trap Locus 2 (Gtl2) long 
noncoding RNA (lncRNA) encoded by the imprinted Gtl2-Dio3 noncoding RNA 
(ncRNA) locus in cardiac muscle. LncRNAshave emerged as important regulators 
of transcription and modulators of the epigenome. Despite its recognized role in 
embryonic stem cell pluripotency, the roles of Gtl2 in the heart are unknown. The 
main purpose of this research will be to elucidate the function of Gtl2’s in 
cardiomyopathy. In addition, this investigation will yield cardiac-specific reagents 
to be used for in vivo studies to further support experiments done in vitro.  
1.2 Long Noncoding RNAs   
Recently, the discovery of microRNAs (miRNAs) and other noncoding 
RNAs (ncRNAs) such as long noncoding RNAs (lncRNAs) has shown that the 
traditional view of gene regulation goes beyond the central dogma of DNA 
(transcription)  RNA (translation)  protein. The sequencing of genomes in 
combination with deep sequencing of transcripts has brought attention to vast 
stretches of non-protein coding DNA regions that transcribe noncoding regulatory 
RNA. Studies have shown that only 2% of the human genome encodes proteins 
and that approximately 60% encodes for transcripts that do not have any protein 
coding capacity (Geisler et al., 2013,Devaux et al., 2015). Of these noncoding 
transcripts, approximately 210,831 lncRNAs have been discovered. This suggests 
that non-coding DNA regions are much more than just “junk.” The expression of 
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lncRNAs is specific to development, stem cell differentiation, and certain organs, 
like skeletal and cardiac muscle, showing that they have precise subcellular 
localization (Mercer et al., 2009).  Initial research has shown that lncRNAs are 
involved in imprint regulation, cell cycle regulation, maintenance of pluripotency, 
chromatin remodeling, and disease (Geisler et al., 2013, Wang and Chang, 2011, 
Mercer et al., 2009).   
LncRNAs are defined as polymerase II RNA transcripts that are greater than 
200 base pairs in length and regulate target-gene expression. Additionally, 
lncRNAs have a 5’-cap, are spliced, and have a polyadenylated tail at the 3’-end. 
LncRNAs do not encode proteins and are typically expressed at low levels. Based 
on the myriad of cellular functions described for lncRNAs and their potential role 
in disease, there is strong rationale to further characterize the many newly 
discovered lncRNAs (Devaux et al., 2013Geisler et al., 2013).    
1.2.1 Long Noncoding RNAs as Transcriptional Regulators  
LncRNAs differ from other ncRNAs, like microRNAs(miRNAs)and messenger 
RNAs (mRNAs), because they have a wide range of functions. LncRNAs are 
mostly found in the nucleus and modulate transcription through epigenetics. A 
small fraction, about 15%, are found in the cytoplasm and act as translational 
regulators (Devaux et al., 2013 Geisler et al., 2013). The cytoplasmic lncRNAs 
either repress or activate gene expression at the translational level by binding to 
mRNAs or capturing miRNAs and stopping them from causing translation 
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repression. The lncRNAs that reside in the nucleus carry out chromatin 
modifications via five mechanisms: signal lncRNAs, decoy lncRNAs, scaffold 
lncRNAs, guide lncRNAs, and enhancer lncRNAs (Wang and Chang, 2011) 
(Figure 1.1). It is important to note that lncRNAs are multifunctional and 
extremely diverse. Thus, many lncRNAs have several modes of action.  
1.2.1.1 Signal LncRNAs  
Signal lncRNAs act as signals because their transcription occurs at a 
specific place and time (Figure 1.1A). The specificity of their transcription allows 
them to interpret development cues, cellular contexts, and respond to various 
stimuli. Additionally, signal lncRNAs can serve as markers for important 
biological events. An example of a signal lncRNA is potassium voltage-gated 
channel subfamily KQT member 1, KCNQIOT1, which is an imprinted paternal 
allele. KCNQIOT1 recruits histone methyltransferases, such as Polycomb 
Repression Complex 2 (PRC2), to the site of chromatin and leads to the 
methylation of histone 3, lysine 27 (H3K27me3). KCNQIOT1 is expressed in the 
placenta during development, which exemplifies the tissue and time specific 
manner of signal lncRNAs (Figure 1.2) (Devaux et al., 2015, Wang and Chang, 
2011, Mohammad et al., 2009).  
1.2.1.2 Decoy LncRNAs 
LncRNAs that are classified as decoys capture transcriptional regulators, 
such as transcription factors, chromatin modifiers, and miRNAs, and this results 
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in transcriptional repression (Figure 1.1B). An example of a decoy lncRNA is 
metastasis associated lung endocarcrinoma transcript 1, MALAT1. MALAT1 is 
localized in the nucleus and controls alternative splicing by trapping SR splicing 
factors. This lncRNA has been shown to be involved in the regulation of 
endothelial and vessel growth (Devaux et al., 2015) (Figure 1.2).  
1.2.1.3 Guide LncRNAs  
LncRNAs can also be characterized as guides, which bind to proteins and 
directs the bound protein complex to specific target (Figure 1.1C). LncRNAs can 
guide alternations in gene expression in cis or trans. An example of a guide 
lncRNA that acts in cis is X inactivation factor center (Xic), which controls the 
silencing of one of the X chromosomes in females by recruiting PRC2. An 
example of a lncRNA that acts in trans is HOX Transcript anti-sense RNA 
(HOTAIR) and it has been linked to primary and metastatic breast cancer. Like 
Xic, it interacts with PRC2 and regulates epigenetic states leading to increased 
cell invasiveness. Guide lncRNAs can bind to repressive complexes, like the 
polycomb group proteins, activating complexes, like the trithorax group proteins, 
or transcription factors. Even though these lncRNAs can both repress and activate 
transcription, they all do so by modulating the epigenome (Greco and Conorelli, 
2015, Wang and Chang, 2011).  
 5 
 
1.2.1.4 Scaffold LncRNAs  
Scaffold lncRNAs form complexes with multiple molecular components 
and can either cause repression or activation of transcription (Figure 1.1D). 
Scaffold lncRNAs can bind to multiple components simultaneously because their 
complex secondary structure has different domains acting as binding site for 
repressive and activator complexes. An example of a scaffold lncRNA is 
CDKN2B Antisense RNA1 (CDKN2B-AS1, or ANRIL). Like many of the other 
lncRNAs, it promotes gene silencing through interactions with the polycomb group 
proteins, PRC 1 and 2. ANRIL specifically silences the INK4b-ARF-INK4a locus 
and alters the expression of genes involved with regulating glucose and fatty acid 
metabolism (Wang and Chang, 2011) (Figure 1.2).   
1.2.1.5 Enhancer LncRNAs  
LncRNAs can also be described as enhancer lncRNAs, which promotes 
the interaction of enhancer and promoter regions of a gene through chromosomal 
looping (Figure 1.1E). Mm85 is an example of an enhancer lncRNA that induces 
the expression of its target gene, Mycod. Mm85 has been shown to play a role in 
embryonic stem cell differentiation (Devaux et al., 2015).  
1.3 Long Noncoding RNAs in Cardiovascular Development and Disease  
There has been increasing evidence that lncRNAs play a role in modulating 
cardiac gene expression. Genetic reprogramming results in alterations in heart 
functions and plays a role in disease pathogenesis. Recently, hundreds of 
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lncRNAs have been identified as having roles in cardiac development and disease, 
but many have yet to be characterized (Devaux et al., 2015). Extra-deep 
sequencing of murine hearts following myocardial infarction have identified 
lncRNAs that are associated with enhancers, chromatin-transition states, and 
epigenetic reprogramming (Grote et al., 2013, Han et al., 2014, Kallen et al., 
2013, Klattenhoff et al., 2013, Wang et al., 2014, Wang et al., 2016).  
1.3.1 Long Noncoding RNAs in Cardiovascular Development 
 
Cardiogenesis, or the development of the heart from pluripotent stem cells 
that differentiate into mature cardiomyocytes, requires extensive coordination of 
gene activation and repression. If this coordination is disturbed, it can lead to the 
development of disorders like congenital heart disease. Also, cardiovascular 
disease and aging leads to the loss of cardiomyocytes and the adult heart has 
minimal regenerative capacity (Grote at al., 2013). Therefore, developing a deeper 
understanding of the molecular switches that control the transition between the 
pluripotent stem cell (or multipotent precursor) and the mature cardiomyocyte 
will help improved treatment strategies for heart-related diseases.  
 Recently, several lncRNAs have been reported to play a role in cardiac 
development. FOXF1 Adjacent Non-coding Developmental Regulatory RNA 
(Fendrr), a lncRNA that is specific to the lateral mesoderm, is essential for the 
proper development of the heart and body wall in mice. Embryonic stem cells (ES 
cells) that did not express Fendrr failed to properly differentiate tissues derived 
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from the lateral mesoderm. Also, embryos lacking Fendrr resulted in the 
upregulation of transcription factors controlling lateral plate and mesoderm 
differentiation and a reduction of PRC2 occupancy on certain promoters. Fendrr 
serves as an ideal example of lncRNAs having more than one mode of action. 
Fendrr acts as a guide RNA by binding to both PRC2 and TrxG/MLL and 
modulates chromatin signatures influencing the expression of certain genes. 
Fendrr also has the capability to bind to dsDNA on target promoters, including 
Foxf1, important for blood vessel formation, and Pitx2, required for heart and 
ventral body development. When Fendrr binds to dsDNA, it forms a triplex 
structure (Grote, et al., 2013) (Figure 1.2).  
 Braveheart (Bvht) is another heart associated lncRNA and was shown to 
be required for the progression of nascent mesoderm toward the cardiac fate. Bvht 
is needed for the activation of a core cardiovascular gene network and its 
downstream target, mesoderm posterior 1 (MesP1), a master regulator of a 
multipotent cardiovascular progenitor. Like many other lncRNAs, Bvht interacts 
with PRC2 by binding to SUZ12 during cardiomyocyte differentiation. Bvht’s 
functions suggests that it is important in the epigenetic regulatory switch between 
the pluripotent and differentiated cell state. Additionally, Bvht is involved in the 
maintenance of the cardiac fate in neonatal cardiomyocytes. Without Bvht, 
neonatal myocytes exhibited a disrupted structure as indicated by smaller cell size 
(Klattenhoff et al., 2013) (Figure 1.2).  
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1.3.2  Long Noncoding RNAs in Cardiovascular Disease 
Cardiovascular disease is usually accompanied with genetic and epigenetic 
remodeling. The mechanisms that control this process are not well understood. 
Recently, several lncRNAs have been shown to play a role in cardiac disease, 
such as hypertrophy. One example of a lncRNA that has been recently associated 
with cardiac disease is cardiac-hypertrophy-associated epigenetic regulator 
(Chaer). Chaer is required for the development of hypertrophy by interacting with 
the EZH2 subunit of PRC2 and interfering with PRC2 targeting genetic loci. This 
interaction is induced by the onset of stress or hormones, such as phenylephrine 
(PE) or angiotensin II (ANGII). Chaer prevents methylation of histone H3 lysine 
27 (H3K27me3) at the promoters of genes involved in cardiac hypertrophy. In 
vivo knockout studies in mice and in vitro knockdown studies in neonatal 
ventricular myocytes (NRVMs) showed the complete loss or significant reduction 
in Chaer expression resulted in attenuation of hypertrophy (Wang et al., 2016).  
 The myosin heavy chain 7 (Myh7) locus encodes for structural proteins 
that are important for heart contraction and anti-sense lncRNA transcripts. All the 
transcripts from the Myh7 locus are cardiac specific and highly expressed in adult 
hearts. It has been shown that pathological stress activates Brg1-Hdac-Parp 
chromatin repressor complex, an inhibitor of Mhrt transcription in the heart. The 
inhibition of Mhrt is required for cardiomyopathy to develop. This suggests that 
Mhrt prevents the heart from becoming hypertrophic or failing. If Mhrt expression 
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is restored to pre-stress conditions, the heart will be protected from hypertrophy 
and failure. Mhrt protects the heart by binding to Brg1, a chromatin-remodeling 
factor that is induced by stress and is needed for hypertrophy and heart failure to 
occur. This prevents Bgr1 from binding to its chromatinized targets and stops it 
from remodeling chromatin (Han et al., 2014) (Figure 1.2).  
 Cardiac hypertrophy related factor (CHRF), is an example of a sponge 
lncRNA. CHRF expression is elevated in NRVMs that are treated with ANGII, 
transverse aortic constriction mouse model (TAC), and human heart failure 
samples. CHRF acts an endogenous sponge for miR-489. When CHRF binds to 
miR-489 in ANGII treated NRVMs, miR-489 expression is reduced leading to 
hypertrophy. Hypertrophy was attenuated in ANGII treated NRVMs upon CHRF 
knockdown, as indicated by increased miR-489 expression levels, decreased ANF 
expression levels, and decreased cross-sectional area. These findings support that 
CHRF is a regulator of cardiac hypertrophy (Han et al., 2014) (Figure 1.2).  
1.4 The MEF2 Transcription Factor Family 
Myocyte enhancer factor 2 (MEF2) is an evolutionarily conserved 
transcription factor that belongs to the MADS transcription factor family. 
Drosophila and Caenorhabditis elegans (C. elegans) only possess a single MEF2 
gene whereas vertebrates have four isoforms – MEF2 A, B, C, and D. The four 
MEF2 isoforms have a conserved N-terminal MADS box and MEF2 domains, 
which are key for DNA binding, dimerization, and co-factor recruitment. MEF2 is 
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important for modulating epigenetic regulatory mechanisms as well as controlling 
the activation of genetic programs involved in differentiation, proliferation, 
morphogenesis, survival and apoptosis of various cell types (Gossett, et al., 1998,. 
Pon and Marra, 2015, Potthoff and Olson, 2007).  Specially, MEF2 is a key 
component of muscle gene regulatory networks and is the only myogenic 
transcription factor known to be associated with the differentiation of all muscle 
types (Olson, 2016).  
Recently our lab has shown that the Gtl2-Dio3 locus is regulated by the 
MEF2A transcription factor. In skeletal and cardiac muscle (Figure 1.3). MEF2A 
knockdown led to a decrease in Gtl2 gene activation and miR expression. In 
skeletal muscle, MEF2A knockout mice display downregulation of the Gtl2-Dio3 
miRs, leading to delayed regeneration. (Snyder at al., 2013). Also, it has been 
shown that the overexpression of Gtl2-Dio3 miR’s 410 and 495 induce 
cardiomyocyte proliferation whereas downregulation of miR 410 and 495 
attenuate cardiac hypertrophy (Clark et al., 2016) (Figures 1.4, 1.5).   
1.5 The Gtl2-dio3 Locus    
The Gtl2-Dio3 locus (Figure 1.6) is located between the DLK1-DIO3 
genomic region, located on human chromosome 14q32. This region contains 
paternally expressed imprinted genes, DLK1, RTL1, and DIO3, and the 
maternally imprinted genes, MEG3, MEG8 (RIAN), and anti-sense RTL1 
(asRTL1) (Benetatos et al., 2012). Expression of this locus is tightly controlled by 
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two different methylated regions (DMRs), the intergenic DMR (IG-DMR) and the 
MEG3-DMR. The imprinted expression of these genes play an important role in 
development, growth, and disease. In addition to the two long intergenic RNAs, 
MEG3 and MEG8, it harbors one of the largest mammalian miRNA clusters. The 
Gtl2-Dio3 locus encodes for 54 miRNAs that have been implicated in cardiac 
function, development, and disease (Zhou et al., 2012). 
 The mouse ortholog to MEG3, Gtl2 (gene trap locus 2), which is located 
on chromosome 12, was initially discovered during a gene trap screen to isolate 
genes with temporally and spatially regulated expression during embryonic 
development (Schuster-Gossler, et al., 1994). The Gtl2 lncRNA gene contains 10 
exons that are alternatively spliced and give rise to many variants. Human MEG3 
has 27 variants and the most highly expressed exons are 1-4 and 8-10 (Zhou et al., 
2012) (Figure 1.7). There are 13 conserved splice variants in pigs, gorillas, and 
mice. The longest splice variant is the most conserved across mammals.  
1.5.1 The Functions of Gtl2 
Gtl2 has regulatory roles in differentiation, cancer progression, genomic 
imprinting and apoptosis. MEG3 has been shown to play a role in cancer. MEG3 is 
not expressed in primary tumors and tumor cells lines, leading to increased cell 
proliferation. Additionally, inactivation of MEG3 leads to a significant increase in 
the expression of angiogenesis promoting genes and micro vessel formation in the 
brain. When MEG3 is reintroduced into cancerous cells or tissues, there is a 
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decrease in cell proliferation and an increase in apoptosis. The expression of 
MEG3 induces accumulation of p53, stimulates transcription from a p53 dependent 
promoter, and regulates p53 target expression. This evidence suggests that MEG3 
is a novel lncRNA tumor suppressor (Zhou et al., 2012).  
Additionally, Zhou et al (2012) generated a Gtl2 knockout (KO) mouse by 
deleting a 5kb region consisting of a deletion of the first 5 exons of the MEG3 
gene as well as a small portion of the MEG3 promoter. Mice carrying the paternal 
deletion were alive and did not exhibit any defects. However, mice carrying the 
maternal deletion died perinatally and suffered severe skeletal muscle defects. 
Several other Gtl2 KO mice were generated (Lin et al., 2007, Takahashi et al., 
2009) and all the KO studies supported the notion that Gtl2 is required for 
maintaining an active, unmethylated IG-DMR and the expression of downstream 
maternal ncRNAs.  
MEG3 has also been shown to play a role in maintaining the chromatin 
signature in embryonic stem cells. Kaneko et al (2014) identified a 30-amino acid 
region of JARID2 that mediates interactions with lncRNAs. The presence of 
lncRNAs stimulated JARID2-EZH2 interactions with chromatin in vivo and 
JARID2 mediated recruitment of PRC2 to chromatin in vitro. RNA 
immunoprecipitation showed MEG3 as well as other lncRNAs from the DLK-
DIO3 locus interacted with PRC2 via JARID2 in embryonic stem cells. Pluripotent 
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stem cells that did not express MEG3 exhibited altered chromatin distribution of 
JARID2, PRC2, and H3K27me3 (Kaneko et al., 2014).  
1.6 Thesis Rationale 
The goal of this study is to characterize the role of the MEF2A-regulated 
Gtl2-Dio3 lncRNA, Gtl2, in cardiac muscle. Previously, we demonstrated that 
MEF2A directly regulates the expression of the Gtl2-Dio3 ncRNA mega cluster 
in skeletal muscle (Snyder et al., 2013). Since the expression of Gtl2 directly 
parallel’s MEF2A expression levels and it is expressed in cardiac muscle, I was 
interested in dissecting Gtl2’s role in cardiac muscle.  
To accomplish this, I examined do so, I will initially examine Glt2 
expression levels in wild type cardiac muscle as well as several cardiomyopathies 
utilizing qRT-PCR. Also, our lab has recently shown that overexpression of Gtl2-
Dio3 miR’s 410 and 495 induce cardiomyocyte proliferation and the 
downregulation of miR’s 410 and 495 attenuate hypertrophy (Clark et al., 2016) 
(Figure 1.6). Since the Glt2-Dio3 locus is coordinately regulated by MEF2A, I 
hypothesized that Gtl2 should have similar effects on cardiomyocytes in vitro. I 
transiently knocked down Glt2 in cardiomyocytes using GapmeRs, chemically 
modified antisense oligonucleotides designed for efficient lncRNA inhibition 
(Grunwellet at al., 2003). After confirming that the Gtl2 specific GapmeRs 
effectively knocked down basal Gtl2 expression levels, I transiently knocked 
down Gtl2 with the GapmeRs in cardiomyocytes treated with phenylephrine (PE) 
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to induce hypertrophy. I monitored the cardiomyocytes for any phenotypic 
changes and performed gene analysis using qRT-PCR to confirm Gtl2 knockdown 
as well as attenuation of hypertrophy by examining Natriuretic peptide precursor 
A and B (Nppb, Nppa) levels.  
Additionally, to complement the above in vitro knockdown experiments, I 
designed a cardiac tropic adeno-associated virus 9 (AAV9) MEG3 DNA for 
overexpression experiments. These experiments will give further insight whether 
modulating Gtl2 expression in the heart promotes proliferation, improves the 
effects of cardiac disease, or changes the epigenetic signature. Further studies 
investigating the roles of Gtl2 in the diseased heart may lead to the development 
of other potential therapies to treat cardiac disease.  
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Figure 1.1 LncRNAs mechanisms of action. LncRNAs can be classified as 
either a signal (A), decoy (B), guide (C), a scaffold, or an enhancer (E). The 
transcription of signal lncRNAs takes place at a specific place and time, thus 
serving as a signal or mark for a specific biological event. A decoy lncRNA 
sequesters transcriptional regulators like repressors, activators, and transcription 
factors. A guide RNA binds to proteins and localizes them to a specific target 
gene. A scaffold lncRNA can bind to multiple repressor or activator complexes at 
once to bring about changes in transcription. An enhancer lncRNA promotes 
interaction between the promoter and enhancer regions of a target gene. (Adapted 
from Greco and Condorelli, 2015). 
Figure 1.2 Illustrating the role of lncRNAs in cardiac pathways. LncRNAs are 
expressed in many the various cell types that make up the heart. The lncRNAs 
that are highlighted in the figure were mentioned in the text. Several of the 
lncRNAs that were discussed – Chaer (involved in disease), Xic (guide lncRNA), 
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HOTAIR (guide lncRNA), and Mm85 (enhancer lncRNA) are not shown in the 
figure. (Adapted from Devaux et al., 2015) 
  
Figure 1.3 MEF2A binds to the Gtl2 proximal promoter and activates Gt12-
Dio3. Mef2a overexpression lead to an increase in luciferase reporter activity, 
indicating that it induces Gtl2 expression. When the Mef2 binding site is mutated, 
Mef2a can no longer bind to the -39 site, resulting in a decrease in luciferase 
activity and reduction in Gtl2 expression (Adapted from Snyder et al., 2013).  
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Figure 1.4 Glt2-Dio3 miRNA’s 410 and 495 induce cardiomyocyte 
proliferation. miR’s410 and 495 were over expressed in NRVMs and Ki67 
immunostaining was performed. α-actinin staining is shown in green, Ki67 
staining is shown in red, DAPI is shown in blue. Graph shows quantification of 
Ki67 staining. The immunostaining showed that miR 410 and 495 overexpression 
resulted in increased number of cells that were Ki67 positive. NC (control) 410, 
495 (miR ovexpressor). (Adapted from Clark et al., 2015). 
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Figure 1.5 Knockdown of Gtl2-Dio3 miRNA’s 410 and 495 lead to the 
attenuation of hypertrophy. Quantitative RT-PCR showed that knockdown of 
miR-410 and 495 in NRVMs treated with PE resulted in the attenuation of 
hypertrophy as indicated by reduced expression of Nppa and Nppb. (Adapted 
from Clark et al., 2016).  
 
Figure 1.6 Diagram of the Gtl2-Dio3 locus. (A) Structure of the Gtl2-Dio3 locus 
which is located on human chromosome 14. The locus is approximately 837kb in 
length and consists of the paternally expressed protein coding genes, DLK1, 
RTL1, and DIO3, and the maternally imprinted genes MEG3, MEG8 (RIAN), and 
anti-sense RTL1 (asRTL1). The locus also encodes 54 miRNAs. The maternal 
chromosome is in red and the paternal chromosome is in blue. The filled in blue 
circles represent methylated and the empty yellow outlined circles are 
unmethylated. (B) Schematic of the MEG3 gene which is 35kb long and consists 
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of 10 exons. The IG-DMR is located upstream of the MEG3 gene and the MEG3 
DMR overlaps with the MEG3 promoter (Adapted from Zhou et al., 2012). 
 
Figure 1.7 Isoforms of MEG3. The MEG3 lncRNA isoforms are generated from 
alternative splicing. The common exons (exons 1-4 and 8-10) are in red. Exon 3a 
(in orange) contains an additional 40 nucleotides. The prevalence of each isoform 
was calculated from taking the average values from five human tissues and cell 
lines. (adapted from Zhou et. al., 2012).  
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CHAPTER 2: Materials and Methods 
2.1   Cell Culture  
2.1.1 Cell Lines 
HEK293T cells were grown in growth medium comprised of Dulbecco’s 
Modified Eagle Medium (DMEM, Invitrogen) that was supplemented with 10% 
fetal bovine serum (FBS, Atlanta Biologics) and 1% Penicillin/Streptomycin/L-
Glutamine (Invitrogen). Cells were kept in a 37°C incubator humidified with 5% 
CO2. When cells reached subconfluency, they were passaged by first washing 
with 1X Phosphate-buffered saline (PBS, Invitrogen), then adding 2 mL of 
trypsin-EDTA (Invitrogen) for 2 to 3 minutes, and resuspending the cells in 8 mL 
of fresh growth media. Cells were commonly passaged at a 1:10 or 1:20 ratio to 
maintain cell lines.  
2.1.2  Neonatal Ventricular Myocytes Isolation  
Neonatal Ventricular Myocytes (NRVMs) were isolated from 1 to2-day 
old male and female Sprague-Dawley rat pups (Charles River Laboratories). 
Usually, hearts were isolated from 9 to 11 neonatal rats. Rat pups were sacrificed 
using cervical dislocation for harvesting the hearts. The hearts were placed 
immediately into a 1X Hank’s Balanced Salt Solution (HBSS, Invitrogen) and 
kept on ice until all the hearts were harvested. Once all the hearts were harvested, 
they were placed into a sterile tissue culture hood for cleaning. The 1X HBSS was 
aspirated off and the hearts were placed in a clean 6 cm culture dish with 5 mL of 
fresh 1X HBSS.  The atria and vessels were dissected from the ventricles. The 
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ventricles were placed into a new 6cm culture dish with 5 mL of fresh 1X HBSS. 
Ventricles were cut into 3 to4 equal sized pieces and washed 3 times with fresh 
1X HBSS. Following the final wash, the ventricles were transferred to 25 mL of 
1mg/mL solution of Trypsin EDTA/1X HBSS (Invitrogen) and kept at 4°C 
overnight.  
The following day, 10 mL of prewarmed 10% FBS growth media was 
added and placed in a shaking 37°C incubator at 100 RPM for 3 minutes. The 
trypsin/media solution was aspirated off and 10 mL of prewarmed 10 mg/mL 
collagenase II (Worthington Biochemical) was added. The hearts were incubated 
in the collagenase II solution for 6 minutes in the 37°C shaking incubator. The 
supernatant containing dissociated cardiomyocytes was transferred to a 50 mL 
falcon tube and placed on ice. This step was repeated 7 times. Once all the 
cardiomyocytes were isolated into two 50 mL falcon tubes, they were centrifuged 
at 4000 RPM for 4 minutes to pellet the cells. The supernatant was aspirated off 
and the pellet of cells was resuspended in 20 mL of 10% FBS growth medium. 
The resuspended cells were centrifuged at 4000 RPM for 4 minutes. The 
supernatant was aspirated off and 10 mL of 10% FBS growth medium was used to 
resuspend the pellet. The 20 mL mixture of cardiomyocytes and 10% FBS growth 
medium was transferred to a 10 cm culture dish and incubated at 37°C for 1 hour 
to allow for the cardiac fibroblasts to adhere first to the plate. After 1 hour, the 
solution was placed on to a new 10 cm culture dish and incubated at 37°C for 
another hour to help reduce the number of cardiac fibroblasts in the NRVM 
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culture. After the final 1 hour incubation, cells were counted using a 
hemocytometer and plated at a density of 1x106 cells/well of 6-well gelatinized 
plates. The next day, the media was removed and replaced with 0.5X Nutridoma 
DMEM (Roche), a low serum media. The media was changed every day 
afterward. For the hypertrophy experiments, NRVMs were also treated with 20 
µM of phenylephrine (Sigma) for 48 hours prior to harvesting RNA.  
2.2 Recombinant DNA Techniques  
2.2.1 Cloning  
To isolate DNA fragments on interest and prepare the vector DNA for sub 
cloning, the appropriate restriction endonuclease reactions were used. In general, 
2µg of DNA was digested with 1 unit of restriction endonuclease and the 
appropriate buffer (NEB) for 3 hours at 37°C. Subsequently, DNA was purified 
by gel extraction with the QIAquick DNA extraction kit (Qiagen) or by 
performing a phenol chloroform extraction. To purify the DNA by gel extraction, 
the digested DNA was combined with 6X loading dye (0.7% xylene cyanol, 0.5% 
bromophenol blue, and 60% glycerol in deionized water (dH2O)) for a final 
concentration of 1X. Samples were electrophoresed on a 0.8% agarose gel 
(BioExpress) consisting of 1X TAE buffer (40mM Tris, 50mM sodium acetate, 
1mM EDTA, pH 8.0) at 125V for approximately 30 minutes. The digested DNA 
was visualized on the gel and photographed under ultraviolet (UV) light. The 
desired DNA fragments were cut out from the gel and purified on QIAquick 
columns using the QIAquick Gel Extraction Kit (Qiagen) per the manufacturer’s 
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instructions. To summarize, 600 µl of buffer QG was added to the cut-out gel 
slices and incubated at 55°C until the gel slice had completely dissolved. The 
solution was then added to the QIAquick column and centrifuged at 14,000 RPM 
at room temperature for 1 minute to bind the DNA. The flow through was 
discarded. 750 µl of Buffer PE was added to the wash column and the sample was 
centrifuged at 14,000 RPM at room temperature for 1 minute. Flow through was 
discarded and the column was centrifuged again at 14,000 RPM at room 
temperature for 1 minute to remove any residual Buffer PE. The column was then 
transferred to a clean 1.7 mL microcentrifuge tube and the DNA was eluted with 
30 µl of Buffer EB and centrifuged at 14,000 RPM at room temperature for 1 
minute.  
To purify DNA with phenol chloroform extractions, dH2O was added to 
the aqueous solution of DNA to achieve a final volume of 100 µl. 100 µl of 
phenol:chloroform was added and mixed by vortexing. The solution was then 
centrifuged for 3 minutes at 14,000 RPM. The top aqueous layer was removed 
and transferred to a new 1.5 mL microcentrifuge tube. 10 µL of 3M sodium 
acetate (NaOAc), pH 5.2, 1 µL of glycogen (20 mg/mL), and 250 µL of cold 
100% ethanol was added to the aqueous layer and incubated at -20°C for 30 
minutes. Following the incubation, the solution was centrifuged for 10 minutes at 
14,000 RPM at 4°C. The supernatant was decanted and 250 µL of cold 70% 
ethanol was added to the pellet for washing. The pellet was washed by 
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centrifuging for 2 minutes at 14,000 RPM and the pellet was dried for 15 to 20 
minutes. Once dry, the pellet was resuspended in 30 µL of dH2O.   
Digested DNA that was purified with gel extraction or phenol chloroform 
extraction was used for ligation reactions. Ligation reactions were performed 
using a 3:1 ratio of restriction enzyme-digested insert DNA to vector DNA 
(~150ng of insert DNA, ~50ng of vector DNA), 10X T4 DNA ligase buffer, T4 
DNA ligase (NEB), and dH2O. The total volume of the ligation reactions was 25 
µl. Ligations were incubated in a thermocycler for 4 hours at 16°C and then were 
used to transform E.coli.  
2.2.2 Transformation of Competent DH5α Cells  
Frozen aliquots of chemically competent DH5α E.coli cells were thawed 
on ice. For transformation reactions using ligation reactions, 50 µl of cells were 
incubated with half of the ligation reaction for 10 minutes on ice. Competent cells 
were then heat-shocked for 30 seconds in a 42°C water bath to permeabilize the 
cell membrane and facilitate the introduction of plasmid DNA into the cells. Fresh 
Luria Broth (LB) (250 µl) was added to the transformed bacteria and cells were 
incubated on ice for 10 minutes. The transformed cells were then allowed to 
recover for 1 hour in a 37°C shaking incubator. Transformed bacteria were plated 
on LB agar plates containing the suitable antibiotic (Amp 100 µg/mL, Kan 50 
µg/mL) to select for clones with the transformed plasmid. Plates were wrapped 
with Parafilm (Bemis) and incubated overnight at 37°C. Individual colonies were 
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then picked and used to inoculate 3 mL overnight liquid cultures containing 
antibiotic. Liquid cultures were used for DNA isolation and preparation.   
2.2.3 Transformation of Stbl2 Cells  
  Stbl2 Cells were used specifically for cloning AAV9 constructs. Frozen 
aliquots of Sbtl2 Max Efficiency Cells (Invitrogen) were thawed on ice. For 
transformation reactions using AAV9 ligation reactions, 200 µl of cells were 
incubated with the entire ligation reaction (20 µl) for 30 minutes on ice. Stbl2 cells 
were then heat-shocked at 42°C for 25 seconds. Fresh LB (250 µl) was added to 
the cells after they were incubated on ice for 2 minutes. The transformed cells 
recovered for 1 hour at 37°C. 200 µl of the transformed cells were plated on LB 
agar plates containing the suitable antibiotic (Amp 100 µg/mL) to select for clones 
with the transformed plasmid. The plates were wrapped with Parafilm (Bemis) and 
incubated overnight for 37°C. Individual colonies were then picked and used to 
inoculate 3 mL overnight liquid culture containing antibiotic. Liquid cultures were 
used for DNA isolation and preparation.   
2.3.4 DNA Preparations  
2.3.4.1 Mini-Prep DNA Preparations  
Mini-prep DNA preparations were used for small-scale DNA preparations. 
First, a single, isolated colony was plucked from a LB agar plate and placed in 3 
mL of LB broth with the appropriate antibiotic. The culture was grown overnight 
in a 37°C shaking incubator. The following day, 1.5 mL of the 3 mL overnight 
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culture was transferred to a 1.7 mL microcentrifuge tube and centrifuged at 
13,000 RPM at room temperature for 1 minute. The supernatant was decanted and 
the pellet was resuspended in 100 µl of Solution #1 (50mM glucose, 10mM 
EDTA pH 8.0, 25mM Tris) and then lysed in 200 µl of Solution #2 (0.2M 
potassium acetate, 11.5% glacial acetic acid). Next, 400 µl of phenol:cholorform 
(1:1) was added and the sample was mixed by vortexing. The top aqueous layer, 
which contained the DNA, was transferred to a new microcentrifuge tube and the 
organic layer was discarded. The DNA was precipitated by adding 800 µl of ice 
cold 100% ethanol. The samples were centrifuged at 13,000 RPM at 4°C for 10 
minutes. The supernatant was decanted, the pellet was washed with 200 µl of 70% 
ethanol, and centrifuged at 13,000 RPM at 4°C for 1 minute.  The supernatant was 
decanted and the pellets were dried for 15 to 20 minutes. Dried pellets were 
resuspended in 20 µl of Baxter water with 0.1 mg/mL RNase and incubated at 
37°C for 15 minutes.  
2.3.4.2 MIDI-Prep DNA Preparations  
 
MIDI-Prep DNA preparations were used for large scale DNA 
preparations. 1 mL of cultured bacteria (either DH5α or Sbtl2) in LB were 
incubated with 100 mL of LB broth containing the appropriate antibiotic in a 
shaking 37°C incubator overnight. The next day, centrifugation at 7,000 RPM at 
4°C for 5 minutes was used to pellet the cells. DNA isolation was done using 
NucleoBond Plasmid Purification MIDI Prep System (BD Biosciences) by 
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following the manufactures instructions. To summarize, the pellet of bacteria was 
resuspended in 4 mL of buffer S1, lysed in 4 mL of buffer S2, and neutralized 
with 4 mL of buffer S3. Prior to passing the solution through the Nucleobond 
column, a folded filter paper was placed into the column and it was equilibrated 
with 2.5 mL of buffer N2. After the solution had completely passed through the 
filter and column, the column was washed three times with 10 mL of buffer N3. 
The column was transferred to a new 15 mL tube and the DNA was eluted with 5 
mL of buffer N5. 3.5 mL of isopropanol was added to the mixture of eluted buffer 
and DNA. The solution was centrifuged at 9,000 RPM for 30 minutes at 4°C. 
Lastly, the DNA pellet was washed with 2 mL 70% ethanol, centrifuged at 9,000 
RPM at 4°C for 5 minutes, allowed to dry and resuspended in 200 µl dH2O, and 
stored at -20°C.  
2.3.4.3 DNA Sequencing  
 
DNA Sequencing was performed by MWG Operon. Pre-mixed samples of 
purified plasmid and primer were supplied for MWG Operon. The forward and 
reverse reactions were pre-mixed and prepared in separate tubes. To prepare the 
pre-mixed samples, 8 µl of 200 ng/µl purified plasmid DNA was combined with 4 
µl of 10pmol AAV9 Sequencing forward or reverse primer (table 2.1).  
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2.4 Transfection Techniques  
2.4.1 General Plasmid Transfection  
General transfections of expression vectors in mammalian cell lines were 
done via lipid-mediated plasma delivery for all experiments. Three different types 
of lipid-mediated transfection reagents were used: TransIT-LTI (Mirus Bio, 
LLC), FuGENE (Roche), and Polyethylenimine (PEI, Polysciences, INC). 
FuGENE and Trans-IT was used at a 3:1 ratio (µL FuGENE:µg DNA) and PEI 
was used at a 6:1 ratio (6 µL PEI:µg DNA). Typically, cells were seeded 24 hours 
before transfection to allow the cells to reach 40 to70% confluency. For all 
transfections, the transfection reagent was warmed to room temperature prior to 
use and added to pre-warmed serum free DMEM (100 µL SF DMEM per 1 µg 
DNA) in a sterile centrifuge tube. The mixture was incubated at room temperature 
for 5 minutes. DNA to be transfected was added to the transfection reagent SF 
DMEM mixture and incubated at room temperature for 15 minutes. The 
complexed DNA and transfection reagent in SF DMEM was added dropwise to 
each plate or well of cells. The cells were incubated with the transfection reagents 
in a 37°C incubator for 24 hours. After 24 hours, the media was replaced with 
fresh media to remove residual transfection reagents. The cells were incubated for 
up to 48 hours before harvesting.  
2.4.2 GapmeR Transfections  
GapmeRs were used for Gtl2 knockdown experiments in NRVMs. For all 
experiments, NRVMs were plated at 1x106 cells/well in a gelatinized 6-well plate 
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24 hours prior to transfection. This allowed for the cells to be approximately 80% 
confluent on the day of transfection. TransIT (Mirus Bio, LLC) or FuGENE 
(Roche) were used as the lipid-mediated transfection reagents. Both TransIT and 
FuGENE were used at a 3:1 ratio (µl of transfection reagent:µg GapmeR). To 
obtain a final concentration of 25 nM, 50 nM, 100 nM in each well, 1.5 µL, 3.0 
µL, or 4.5 µL of a 50 µM GapmeR stock was required.  The pre-warmed 
transfection reagent, GapmeRs (25 nM, 75 nM, 100 nM), pre-warmed OptiMEM 
were mixed by gently pipetting up and down and allowed to incubate at room 
temperature for 15 to 30 minutes. Following the incubation, the transfection 
reagent GapmeR complex mixture was added dropwise to each well and 
incubated in at 37°C until it was time to harvest the cells. For Gtl2 basal 
knockdown experiments, RNA was harvested from the NRVMs 48 hours after 
transfection. For hypertrophy experiments, NRVMs were treated with 20 µM of 
PE 24 hours after transfection and RNA was harvested from the NRVMs 48 hours 
after the addition of PE.   
2.5 Cell Based Assays  
2.5.1 Luciferase Assays 
Luciferase assays were performed 24 to36 hours post transfection using 
Luciferase Assay Reagent (LAR, Promega) if normalizing using a β-galactosidase 
assay (section 2.5.2) or Luciferase Assay Reagent II (LARII, Promega) if 
normalization using TK-Renilla. Luciferase assays were also normalized using 
Bradford Assays (section 2.5.3).  
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Cells were harvested for the luciferase assay by washing with non-sterile 
1X PBS and lysing with 1X Passive lysis buffer (Promega) by gently shaking for 
20 minutes. To measure luciferase activity, 10 µL of cell lysate was transferred to 
a microcentrifuge tube, 50 µL of LAR was added, vortexed to mix, placed inside 
the luminometer, and light absorbance was measured for 10 seconds. To measure 
Firefly luciferase activity, 10 µL of cell lysate was transferred to a 
microcentrifuge tube, 50 µL of LARII was added, vortexed to mix, placed inside 
the luminometer, and light absorbance was measured for 10 seconds. Following 
the first reading, 50 µL of 1X Stop and Glo reagent (Promega) was added and 
Renilla measures were taken. Firefly luciferase relative light units were 
normalized to Renilla light absorbance values and then fold change in activity 
over reporter was calculated per sample.  
2.5.2 β-galactosidase Assays  
Β-galactosidase (β-gal) assays were performed in a 96-well plate. To 
measure β-gal activity 10 µL of cell lysate was aliquoted in a 1.7 mL 
microcentrifuge tube and incubated with 135 µL of assay mix (15 µL 10X Z-
buffer (100 mM NaH2PO4, 10 mM KCl, 1mM MgSO4), 16.5µL 8 mg/mL ONPG, 
0.2 µL β-mercaptoethanol, and 103.5 µL dH2O) until a light-yellow color 
developed. To stop the reaction, 250 µL of 1M Na2CO3 was added to each sample 
and vortexed to mix. 200 µL of the reaction was pipetted into a 96-well plate. 
Samples were read on a 96-well plate reader (Model 550, Bio-Rad) at a 
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wavelength of 415 nm. β-gal readings were used to normalized firefly luciferase 
readings using LAR.  
2.5.3 Bradford Assays 
Bradford Assays were used to measure total protein in a sample. 5 µL of 
cell lysate were pipetted into a 96-well plate. The Bradford Solution (BioRad) 
was diluted 5:1 with dH2O and then pipetted into the 96-well plate with the cell 
lysate. The cell lysate and diluted Bradford solution was mixed by pipetting up 
and down several times. The samples were allowed to stand for two minutes 
before reading the plate at 594 nm.  
2.6 RNA Techniques  
2.6.1 RNA Isolation (Cell Culture)  
Cells were first washed with 1X PBS and RNA was isolated using TRIzol 
reagent (Invitrogen). The volume of the TRIzol reagent was dependent on the size 
of the culturing dish (350 µL for a 6-well dish, 500 µL for a 6 cm dish, 1000 µL 
for a 10 cm dish). After the TRIzol was added to the dish, the cells were removed 
from the plates’ surface by scraping with a cell scraper. The cell and TRIzol 
mixture were transferred to a 1.7 mL microcentrifuge tube and incubated for 5 
minutes at room temperature. 200 µL of chloroform per 1000 µL of TRIzol/cells 
was added to the mixture. The tubes were mixed by shaking vigorously and then 
incubated for to 3 minutes at room temperature. To separate the aqueous from the 
organic layer, the samples were centrifuged at 11,400 RPM for 15 minutes at 4°C. 
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The top layer was removed, transferred into a new 1.7 mL microcentrifuge tube, 
and 500 µL of isopropanol per 1 mL of TRIzol was added. The mixture was 
mixed by inversion and incubated at -20°C for at least an hour and then 
centrifuged at 11,400 RPM for 30 minutes at 4°C. The supernatant was decanted, 
the pellet was washed with 1 mL (per 1 mL of TRIzol) of 70% ethanol, and 
centrifuged at 11,400 RPM for 5 minutes at 4°C. The pellet was dried for 15 to20 
minutes and then resuspended in 40 µL of dH2O (volume was adjusted based on 
the size of the pellet). RNA was stored at -80°C.   
2.6.2 Reverse Transcription  
The concentration of the extracted RNA (refer to section 2.6.2) was 
measured by spectrophotometry using the NanoDrop. cDNA was generated with 
2000 ng of RNA. The cDNA was generated using M-MLV Reverse Transcriptase 
and associated reagents (Promega). Reverse transcription reactions were done in 
two steps. The first part of the Reverse Transcription reaction consisted of 2000 
ng of RNA in a 9.3 µL final volume, 3 µL of 2.5 µM dNTPs (NEB), and 15.4 µM 
Random Primers (Promega). The reaction was denatured at 65°C for 5 minutes 
using a heat block. After the 5 minute denaturation step, the reactions were 
incubated on ice for 5 minutes. Next, 3 µL of 5X M-MMLV Buffer (Promega), 
0.5 µL of M-MMLV Reverse Transcriptase (Promega), and 0.5 µL of RNAsin 
was added to the reaction mixture. The reactions were incubated for 1 hour at 
37°C in the thermocycler. cDNA was stored at -20°C.  
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2.6.3 Polymerase Chain Reaction (PCR)  
 Polymerase Chain Reaction was performed for amplification of DNA 
fragments for cloning and for gene expression analysis for semi-quantitative 
methods. To amplify DNA from genomic or cDNA, the typical protocol was 
100ng-1µg DNA template, 2.5 µL of Thermo-Polymerase Buffer (NEB), 2 µL 2.5 
mM dNTPs (NEB), 1 µL 25 µM gene specific primers (forward and reverse), 0.5 
µL Taq Polymerase (NEB), and 18.5 µL dH2O. Each reaction mixture was gently 
mixed and centrifuged quickly prior to placing it in the thermocycler for PCR. 
The PCR program that was most frequently used was denature for 4 minutes at 
94°C, then 23 to30 cycles of 94°C for 30 seconds, 56 to62°C for 30 seconds (this 
temperature was dependent on the primers’ Tm), 68°C for 30 seconds, and a final 
extension for 10 minutes at 68°C. The PCR reactions were then kept at 4°C in the 
thermocycler until they were removed to be stored at -20°C.  
2.6.4 Semi-Quantitative RT-PCR 
Semi-quantitative RT-PCR was done in a 25 µL reaction. The reaction 
consisted of 1 µL cDNA, 2.5 µL 10X Taq Buffer (NEB), 2.5 µL dNTPs, 1 µL 
primer mix (1:2:1 ratio of 100 µM Forward Primer: Baxter dH2O: 100 µM 
Reverse Primer), and 18.25 µL Baxter dH2O. The PCR reaction was subjected to 
PCR program using a thermocycler. The PCR program used was initial 
denaturation at 94°C for 4 minutes, denaturation at 94°C for 1 minute, annealing 
(temperature is dependent on the primers’ Tm), steps 1 to3 were repeated 34 more 
times, final elongation at 72°C for 5 minutes, and held at 4°C. The samples were 
 34 
 
stored at -20°C. The PCR reaction was run on a 0.8% (or greater percentage) 
agarose gel with ethidium bromide to visualize product bands. Primers that were 
used for semi-quantitative PCR are listed in table 2.1.  
2.6.5 Quantitative RT-PCR  
qRT-PCR was done using the Power SYBR Green Master Mix 
(Invitrogen) with the ABI Prism 7900HT Sequence Detection System (Applied 
Biosystems). Each sample was run in triplicate on a 384-well plate (Applied 
Biosystems). Each reaction contained 15 µL of SYBR Green Master Mix, 8 µL of 
dH2O, 6 µL primer mix (5µL 100 µM forward primer, 5 µL reverse primer, and 
190 µL dH2O), and 1 µL cDNA. 8.5 µL of each sample was plated per well in 
triplicate. Plates were centrifuged and underwent thermocycling. The program 
used was 50°C for 2 minutes, 95°C for 10 minutes, 95°C for 15 minutes 
annealing, 60°C for 1 minute, steps 3 to4 were repeated 39 more times. SDS 2.2.4 
software (Ambion) was used to analyze the data and CT values were compared 
between gene specific primers and controls. The CT value for each gene were 
average and subtracted from the average internal control (18s rRNA) to find the 
△CT. The △△CT was found by subtracting the △CT of the control condition from 
the △CT of the experimental condition. Fold changes were calculated using the 
formula FC=2-△△CT. To determine if differences between gene expression were 
statistically significant, a student t-test was used. A p value of ≤0.05 was 
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considered statistically significant. Primers that were used for qRT-PCR are listed 
in table 2.1.  
2.7 Statistical Analysis  
All quantification shown is the mean ± standard error of the mean S.E.M. 
of at least three samples from experiments that were done independently. 
Statistically significant differences between two sets of data were determined by 
the student’s paired t-test. P-values ≤ 0.05 were classified as statistically 
significant.  
  Table 1 Oligonucleotide table. 
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CHAPTER 3: Results and Discussion 
3.1 Results  
3.1.1 Generation of Diagnostic Tools to Use in Gtl2 Knockdown Experiments  
To measure Gtl2 expression in NRVM experiments, it was necessary to 
generate rat specific NRVM primers. Since Gtl2 has multiple variants, I designed 
three different primer sets that amplified different regions of Gtl2 lncRNA and 
were specific to all three mouse Gtl2 lncRNA variants and the best characterized 
rat Gtl2 lncRNA variant. The three primer pairs were validated using semi-
quantitative PCR. Only one primer pair gave optimal results. The 121-base pair 
(bp) expected band was the only apparent band and there was no evidence of off 
target amplification (Figure 3.1). Based on these results, these “Rat Gtl2” primers 
were used for all further gene expression analyses.  
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Figure 3.1 Rat Gtl2 primers are specific. Rat Gtl2 primers amplify all three 
mouse variants as well as the best characterized rat variant. Rat Gtl2 primers were 
validated with semi-quantitative PCR and using wild type NRVM (NRVM WT) 
as the template. The PCR reactions were electrophoresed on a 2.5% ethidium 
bromide agarose gel. The amplicon was the expected band size of 121 bp (as 
indicated by the arrow).   
3.2 Gtl2 Expression in Different Cardiomyopathies  
3.2.1 Gtl2 Expression in Myocardial Infarction  
 
The Naya lab previously examined the expression of (miRNAs)in the 
Glt2-Dio3 noncoding RNA locus in a heart injury model by surgically inducing 
myocardial infarction (MI) in mice. Temporal expression of miR-410, -433, -495 
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and lncRNA Gtl2 were analyzed in the progression of this cardiac injury at day 1, 
3, and 7 days post myocardial infarction. Additionally, spatial expression 
differences in the remote (RM) and infarcted areas (IA) were examined. One day 
post MI, there was a lesser yet significant upregulation of the miRNAs in the RM 
that was not seen in the IA. In contrast, 3 days post injury, the expression of these 
miRNAs was upregulated in both IA and RM. 7 days post MI, the miRNA levels 
remained upregulated, but returned to levels that were observed 3 days post 
myocardial infarction (Clark et al., 2016).  
Since the Gtl2-Dio3 miRNAs exhibited differences in its temporal and 
spatial expression levels 1, 3, and 7 days post myocardial infarction, I wanted to 
determine if Gtl2 had a similar expression profile to the miRNAs. I performed 
expression analysis of Gtl2 by using newly obtained day 7 IA and RM MI tissue 
samples and different Rat specific Gtl2 primers (refer to section 3.1.1 and (Figure 
3.1). I observed a higher upregulation of Gtl2 expression 7 days post myocardial 
infarction as well as increased Gtl2 expression in IA compared to RM (Figure 
3.2), which is consistent with the analysis done previously in our lab (Clark, 
2016). However, there were differences between the fold changes in Gtl2 
expression I obtained and the those obtained previously (Clark, 2016). The 
differences in expression levels could be attributed to sample variation and the use 
of different primers to amplify Gtl2. To confirm that Gtl2 lncRNA expression is 
induced by MI, additional qRT-PCR analyses will need to be performed to 
determine if it is a sample specific effect. 
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3.2.2 Gtl2 Expression in Angiotensin II Treated Heart In Vivo 
  
Clark et al (2016) also examined Gtl2-Dio3 ncRNA expression levels in response 
to pathological cardiac hypertrophy. Expression of miR 410, 433, and Gtl2 were 
examined 3, 7, and 14 days post administration of ANGII. ANGII is a cardiotoxic 
hormone that is known to induce hypertension and hypertrophy in the heart 
(Matsumoto et al., 2013). Like what was observed at 1 day post MI, Gtl2 lncRNA 
expression levels were about two-fold higher than miR’s 410, 433, and 495. On days 
7 and 14 after ANGII administration Gtl2 lncRNA and miR’s 410, 433, and 495 were 
all significantly upregulated relative to sham control. Gtl2 lncRNA expression levels 
increased 15-fold on day 7, which is at least 2-fold greater than any of the three miRs, 
and decreased to similar expression levels that were detected at day 3. It is important 
to note that on both days 7 and 14, Gtl2 lncRNA expression levels were greater than 
the miRs (Clark, 2016).  
I repeated the expression analysis of Gtl2 lncRNA following ANGII 
administration utilizing the same rat specific primers (refer section 3.1.1 and Figure 
3.1) used for the Gtl2 lncRNA expression analysis in day 7 MI samples. Gtl2 lncRNA 
expression levels were 2.7-fold (day 3), 1.6-fold (day 7), and 1.25-fold (day 14) 
upregulated compared to sham control (Figure 3.3). I did not observe the similar 
magnitude of increase in Gtl2 lncRNA expression levels as Clark (2016) found. 
However, this difference could be attributed to the different use of primers and the 
variability in fold changes between samples. To confirm that Gtl2 lncRNA expression 
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is induced by ANGII administration, additional qRT-PCR analyses will need to be 
performed to determine if it is a sample specific effect. 
 
Figure 3.2 Gtl2 lncRNA expression 7 days post myocardial infarction. 
Quantitative RT-PCR of Gtl2 lncRNA 7 days post myocardial infarct. Expression 
is relative to 18S internal control. Gene expression values in sham control tissue 
were normalized to 1. Relative fold change represents the fold change in Gtl2 
lncRNA gene expression in RM and IA tissue compared to control tissue. Sham 
ventricle (control); Remote/uninjured ventricle (RM); Infarcted/injured ventricle 
(IA). Error bars represent S.E.M. n ≥3.  
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Figure 3.3 Gtl2 lncRNA expression 3, 7, and 14 days post ANGII 
administration. Quantitative RT-PCR of Gtl2 lncRNA 3, 7 and 14 days post 
ANGII administration. Expression is relative to 18S internal control. Gtl2 
lncRNA expression values in sham control tissue was normalized to one. Relative 
fold change represents the fold change in Gtl2 lncRNA gene expression in tissue 
sampled from 3, 7, and 14 days post ANGII administration compared to sham 
control tissue. Sham ventricle (control); D3, D7, D14 (day in which tissue was 
sampled following ANGII administration). Error bars represent S.E.M. n ≥3. 
3.3 Knocking Down Gtl2 expression levels In Vitro Utilizing GapmeRs  
GapmeRs were used as the primary reagent to knockdown Gtl2 in vitro 
because they have previously been shown to effectively knockdown lncRNAs. In 
addition, these antisense oligonucleotides are promising candidates for RNA 
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therapeutic technology (Kole et al., 2005). GapmeRs, or anti-sense 
oligonucleotides, are single stranded molecules that are specific to their RNA 
target. End modifications are engineered on the ends of the GapmeR to increase 
their stability in the cell. When introduced, GapmeRs sequester their target RNA 
and it is cleaved by RNase H activity (Kole et al., 2005).  
Before conducting any in vitro hypertrophy experiments, it was necessary 
to determine if the Gtl2 specific GapmeRs robustly downregulated basal Gtl2 
expression levels in NRVMs. I performed a dose response experiment in NRVMs 
to determine which concentration, 25 nM, 50 nM, or 100 nM, was necessary to 
knockdown Gtl2 levels. The first dose response experiment was done by 
performing forward transfection, meaning the GapmeRs (25 nM, 50 nM, or 100 
nM) were transfected 24 hours post seeding the NRVMs. qRT-PCR was 
completed to determine which dose was most effective in knocking down basal 
Gtl2 expression levels. It was found that 25 nM, 50 nM, and 100 nM, resulted in -
3.85-fold, -1.21-fold, and -2.56-fold reduction in basal Gtl2 expression levels, 
respectively, relative to scramble GapmeR control (Figure 3.4). 
To further optimize the experimental procedure for GapmeR transfections, 
I performed a second dose response experiment utilizing the reverse transfection 
approach. In contrast to forward transection, reverse transfection required that the 
transfection and the cells are seeded at the same time. Reverse transfection is 
commonly used to transfect cells that are difficult to transfect and have lower 
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transfection efficiency, like NRVMs. Therefore, I decided that it would be 
beneficial to investigate if transfecting the GapmeRs with this method would 
further decrease basal Gtl2 knockdown. 25 nM and 50 nM of GapmeR were 
reverse transfected in NRVMs and this resulted in -2.25-fold and -1.22-fold 
reduction in basal Gtl2 expression, respectively, relative to Scramble GapmeR 
control (Figure 3.5). Since reverse transfection did not result in a further decrease 
in basal Gtl2 expression levels compared to forward transfection, forward 
transfection was utilized for the in vitro hypertrophy GapmeR experiments. 
Additionally, a concentration of 25 nM GapmeR was utilized for the in vitro 
hypertrophy GapmeR experiments since it resulted in the greatest reduction in 
Gtl2 expression levels (-3.85-fold) (Figure 3.4). 
  
Figure 3.4 Gtl2 lncRNA expression levels following forward transfection with 
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Gtl2 specific GapmeRs. Quantitative RT-PCR of Gtl2 lncRNA post forward 
transfection with Gtl2 specific GapmeRs. Expression is relative to 18s internal 
control. Gl2 lncRNA expression values in Scramble GapmeR treated NRVMs 
were normalized to 1. Relative fold change represents the fold change in gene 
expression in NRVMs transfected with 25 nM, 50 nM, or 100 nM of Gtl2 specific 
GapmeR compared to NRVMs transfected with 25 nM, 50 nM, or 100 nM of 
Scramble GapmeR. Scramble 25 nM, 50 nM, or 100 nM (control); Gtl2 25 nM, 
50 nM, or 100 nM (experimental condition). Experiment completed with an n of 
1.  
 
Figure 3.5 Gtl2 lncRNA expression levels following reverse transfection with 
Gtl2 specific GapmeRs. Quantitative RT-PCR of Gtl2 lncRNA post reverse 
transfection with Gtl2 specific GapmeRs. Expression is relative to 18s internal 
0
0.2
0.4
0.6
0.8
1
1.2
Scramble
25nM
Gtl2 25nM Scramble
50nM
Gtl2 50nM
R
e
la
ti
v
e
 F
o
ld
 C
h
a
n
g
e
 45 
 
control. Gtl2 expression levels in Scramble GapmeR treated NRVMs were 
normalized to 1. Relative fold change represents the fold change in Gtl2 lncRNA 
gene expression in NRVMs transfected with 25 nM or 50 nM of Gtl2 specific 
GapmeR compared to NRVMs transfected with 25 nM or 50 nM of Scramble 
GapmeR. Scramble 25 nM, 50 nM (control); Gtl2 25 nM, 50 nM (experimental 
condition). Experiment completed with an n of 1. 
3.4 Exploring the Role of Gtl2 in In Vitro Hypertrophy Experiments 
After establishing that 25 nM of Gtl2 specific GapmeR robustly knocked 
down basal Gtl2 lncRNA expression in vitro (Figure 3.4 and Figure 3.5), I sought 
to determine if knockdown of Gtl2 played a role in hypertrophy in 
cardiomyocytes. Since it was shown that reduction in Gtl2-Dio3 miRNA 
expression in PE-treated NRVMs lead to attenuation of hypertrophy (Clark et al., 
2016), I hypothesized that the reduction Gtl2 lncRNA would have a similar effect. 
Hypertrophy was significantly induced in NRVMS treated with PE as shown by 
the significant increase in the expression of hypertrophic marker genes, Nppa 
(ANF) and Nppb (BNP). Nppa expression levels increased 23.29-fold and Nppb 
levels increased 17.75-fold in NRVMS treated with PE. However, PE did not 
induce Gtl2 lncRNA expression. Gtl2 lncRNA expression levels were unchanged 
(-1.09-fold decrease). Also, the Gtl2 specific GapmeRs did not robustly 
knockdown Gtl2 lncRNA expression levels in PE treated NRVMs and as a result, 
hypertrophy did not appear to be modulated. Gtl2 lncRNA expression levels 
remained unchanged post GapmeR forward transfection (-1.01-fold change) 
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(Figure 3.7A).  Nppa expression levels were unchanged (1.19-fold increase) and 
Nppb expression levels increased by 4.07-fold (Figure 3.7B). Based on these data, 
we cannot confirm that knocking down Gtl2 lncRNA expression levels results in 
the modulation of cardiac hypertrophy in vitro.  
 
  
  
Figure 3.6 Phenylephrine hypertrophic marker genes in vitro. Quantitative 
RT-PCR of cardiac hypertrophy marker genes Nppa (ANF) and Nppb (BNP) in 
PE-treated NRMVS compared to PBS-treated control NRVMs. Expression is 
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relative to 18s internal control. Gene expression values for PBS-treated NRVMs 
were normalized to one. Relative expression represents the fold change in gene 
expression in PE-treated NRVMs compared to PBS-treated NRVMs. Error bars 
represent S.E.M. n ≥3, *, p≤0.05, **, p≤0.01.  
  
Figure 3.7 Gtl2 expression levels in NRVMS treated with phenylephrine. 
Quantitative RT-PCR of Gtl2 lncRNA in PE-treated NRVMs. Expression is 
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relative to 18s internal control. A) Gene expression values for PBS-treated 
NRVMs were normalized to one. Relative expression represents the fold change 
in gene expression in PE-treated NRVMs compared to PBS-treated NRVMs. B) 
Gene expression values of Gtl2 in PE-treated NRVMs transfected with Gtl2 
specific GapmeR. Relative expression represents the fold change in gene 
expression in PE-treated NRVMs transfected with Gtl2 specific GapmeRs 
compared to PE-treated NRVMs transfected with Scramble GapmeR. Error bars 
represent S.E.M. n≥3. 
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Figure 3.8 Hypertrophy maker genes expression levels in NRVMs treated 
with phenylephrine and transfected with Gtl2 specific or scramble GapmeR. 
Quantitative RT-PCR of Gtl2 lncRNA in PE-treated NRVMs. Expression is 
relative to 18s internal control. A) Nppa (ANF) gene expression values for PBS-
treated NRVMs were normalized to one. Relative expression represents the fold 
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change in gene expression in PE-treated NRVMs compared to PBS-treated 
NRVMs. B) Gene expression values of Nppb (BNP) in PE-treated NRVMs 
transfected with Gtl2 specific GapmeR. Relative expression represents the fold 
change in gene expression in PE-treated NRVMs transfected with Gtl2 specific 
GapmeRs compared to PE-treated NRVMs transfected with Scramble GapmeR. 
Error bars represent S.E.M. n ≥3. 
3.4 Troubleshooting – Alternative Methods and Reagents to Improve Gtl2 
Knockdown In Vitro 
 
3.4.1 Troubleshooting ways to improve GapmeR Knockdown Efficiency  
 
The lack of the GapmeR’s efficiency for robustly knocking down Gtl2 
levels could be due to the secondary structure of Gtl2 lncRNA inhibiting efficient 
binding of the GapmeR. Also, it could be because of the difference in time post 
transfection that RNA was harvested from the NRVMs in the basal knockdown 
and in vitro hypertrophy experiments. RNA was harvested 48 hours post 
transfection for the basal knockdown experiments, whereas RNA was harvest 72 
hours post transfection (refer to methods section 2.4.2). Since GapmeRs 
transiently knockdown their target genes, it is possible that harvesting RNA at 72 
hours post transduction causes one to miss the timepoint when the Gtl2 lncRNA 
expression levels is most reduced. Also, the longer time window could allow Gtl2 
lncRNA expression levels to return to normal levels with the cell.  
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To explore this possibility, I performed the in vitro hypertrophy 
experiments with different methods. I forward transfected PE-treated NRVMs 50 
nM GapmeR, which was double the concentration used in all other in vitro 
hypertrophy experiments, and harvest RNA 48-hours post PE treatment and 72-
hours post transfection. Alternatively, I forward transfected PE-treated NRVMs 
with 25 nM of GapmeR 24 hour prior to PE treatment as well as transfecting with 
25 nM of additional GapmeR 24-hour post PE treatment and harvested RNA 48 
post PE treatment and 24 hours post the second transfection. Gtl2 lncRNA 
expression levels decreased by -1.33-fold and -1.88-fold in NRVMs transfected 
twice with 25 nM GapmeR and once with 50 nM GapmeR respectively (Figure 
3.9A). However, a reduction in hypertrophy makers was not observed for either 
GapmeR concentration (Figure 3.9B, C). These results suggest that a higher dose 
of GapmeR is needed to sufficiently reduce Gtl2 lncRNA expression levels. The 
lack of modulation of hypertrophy could be because Gtl2 lncRNA expression 
levels need to be further reduced or that it does not attenuate hypertrophy. 
To attempt to further optimize the GapmeR concentrations required to 
knockdown Gtl2, I performed another dose response using concentrations of 50 
nM, 75 nM, and 100 nM. The 100 nM GapmeR concentration resulted in a -1.62-
fold reduction in Gtl2 lncRNA expression levels (Figure 3.9). Similar to the 
previously described troubleshooting experiment (Figure 3.1.1), these results 
further support that a higher concentration of GapmeR is required for Gtl2 
knockdown.  
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Figure 3.9 Gene Expression levels of phenylephrine treated NRVMs 
transfected with different concentrations of Gtl2 specific and scramble 
GapmeR. Quantitative RT-PCR of Gtl2 lncRNA and hypertrophy markers ANF 
(Nppa) and BNP (Nppb) post reverse transfection with different concentrations of 
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Gtl2 specific and Scramble GapmeRs. Expression is relative to 18s internal 
control. Gene expression values in Scramble GapmeR treated NRVMs were 
normalized to 1. A) Gtl2 lncRNA expression levels in PE-treated NRVMs 
transfected with either 25 nM Gtl2 specific and Scramble GapmeR 24 hour prior 
to addition of PE and 24 hours post addition of PE or 50 nM of Gtl2 specific and 
Scramble GapmeR 24 hour post addition of PE. B) Nppa (ANF)and C) Nppb 
(BNP)  expression levels in PE-treated NRVMs transfected with either 25 nM 
Gtl2 specific and Scramble GapmeR 24 hour prior to addition of PE and 24 hours 
post addition of PE or 50 nM of Gtl2 specific and Scramble GapmeR 24 hour post 
addition of PE. Experiment was done with an n of 1.  
 
Figure 3.1.1 Gtl2 Expression following forward transfection with Gtl2 
specific GapmeRs at 50 nM, 75 nM and 100 nM concentrations. Quantitative 
RT-PCR of Gtl2 lncRNA post forward transfection with Gtl2 specific GapmeRs. 
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Expression is relative to 18s internal control. Gene expression values in Scramble 
GapmeR treated NRVMs were normalized to 1. Relative fold change represents 
the fold change in gene expression in NRVMs transfected with 50 nM, 75 nM, or 
100 nM of Gtl2 specific GapmeR compared to NRVMs transfected with 50 nM, 
75 nM, or 100 nM of Scramble GapmeR. Experiment completed with an n of 1. 
3.4.2 Exploring an Alternative Knockdown Approach: Utilizing Short-
Hairpin RNAs (shRNA) to Knockdown Gtl2 In Vitro  
 
 Since the GapmeRs were not yielding consistent and robust reduction in 
Gtl2 expression levels in vitro, utilizing shRNA to knockdown Gtl2 expression 
levels was considered. The design of the shRNA was based on the Gtl2 GapmeR 
sequence. For this experiment, NRVMs were transfected with either 
pENTR/shMEG3 or pENTR/lacZ and expression levels were compared by qRT-
PCR analysis. Gtl2 expression levels were dramatically decreased -6.6-fold 
(Figure 3.1.2). This experiment will be repeated several times to confirm that this 
robust result is real and reproducible.  
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Figure 3.1.2 Gtl2 expression following forward transfection with shMEG3. 
Quantitative RT-PCR of Gtl2 lncRNA post forward transfection with shMEG3. 
Expression is relative to 18s internal control. Gene expression values for NRVMs 
transfected with pENTR/lacZ. were normalized to 1. Relative fold change 
represents the fold change in gene expression in NRVMs transfected with 
pENTR/shMEG3 compared to NRVMs transfected with pENTR/LacZ. 
Experiment completed with an n of 1. 
3.5 Designing a Cardiac-trophic Adeno-associated Virus 9 (AVV9) and 
Adenovirus encoding MEG3 for Overexpression Experiments 
 
 3.5.1 Designing an Adeno-associated Virus 9 (AAV9) encoding MEG3 for 
Overexpression Experiments  
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Recombinant adeno-associated virus (rAAV) is an attractive vehicle for 
cardiac gene delivery because it is nonpathogenic, small, can be easily injected, 
and can persist for a long period of time in infected cells (Pacak et al., 2006). 
rAAV is a single stranded DNA virus that needs a helper to replicate and has 
different tropisms, making it ideal for targeting specific tissue types. It has been 
found that rAAV9 is highly cardio-trophic and is able to transduce myocardium at 
200-fold higher than other rAAV types (Pacak et al., 2006). For these reasons, I 
decided to design a rAAV9 MEG3 for in vivo experiments (rAAV9/MEG3).  
The human variant of Glt2, MEG3, was used for designing the rAAV9 
overexpressor. Since human MEG3 and rodent Gtl2 display high sequence 
conservation, overexpressing with the human variant will not be problematic. The 
rAAV9 vector I used for cloning encodes a cardiomyocyte specific promoter, the 
chicken cardiac troponin T (cTNT) promoter, upstream from the multiple cloning 
site (MCS).  The MCS is flanked by restriction sites for NheI and KpnI. Since 
there is a recognition site for Nhel in the middle of the MEG3 sequence, I had to 
develop an alternative cloning strategy. In summary, the alternative strategy I 
devised was generating a forward primer encoding the recognition site for XbaI, 
which has complementary overhangs to NheI, and a reverse primer encoding the 
recognition site for KpnI. These primers were used for amplifying MEG3 with 
semi quantitative PCR (methods section 2.6.5). Following amplification of MEG3 
with semi-quantitative PCR, MEG3 was digested with XbaI and KpnI and rAAV9 
vector was digested with NheI and KpnI (methods section 2.3.1). The digested 
 57 
 
insert and vector were ligated together (methods section 2.3.1), Stbl2 cells were 
transformed with the entire ligation reaction, and the transformed cells were 
plated on ampicillin agar for selection (methods section 2.3.3). The ten positive 
clones were screened for the MEG3 insert by diagnostic digest and one clone 
appeared to be positive for the MEG3 insert. The result from the diagnostic 
digests will be further confirmed with sequencing.  
3.5.1 Designing an Adenovirus encoding MEG3 for Overexpression 
Experiments 
NRVMs are difficult to transfect and typically have low transfection 
efficiency, which can be an issue when performing knockdown and 
overexpression experiments in vitro. Therefore, using lipid mediated transfection 
reagents, such as PEI, Trans-IT, or FuGENE, is not an efficient approach to 
introduce the overexpression or knockdown construct into NRVMs. To overcome 
the limitations of lipid mediated transfection reagents, adenovirus transduction is 
the alternative method of choice. To have a reagent that can effectively introduce 
a MEG3 expression vector in NRVMs, I designed a MEG3 adenovirus 
(pAD/MEG3) for overexpression experiments. These in vitro experiments will be 
used to complement the in vivo experiments utilizing rAAV9/MEG3.  
To summarize, I generated pAD/MEG3 by cloning MEG3 (the same 
MEG3 sequence cloned into rAAV9/MEG3) into pENTR/CMV. pENTR/MEG3 
and pAD-Easy1 were used to co-transform DH5α E.coli in order to join the two 
 58 
 
constructs by homologous recombination. Subsequently, the transformed cells 
were plated on kanamycin agar for selection. Currently, I am screening the 
positive clones to confirm that pENTR/MEG3 successfully recombined with 
pAD-Easy1 by performing diagnostic digests with PacI.   
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CHAPTER 4: Future Directions 
I have generated several reagents to be used for overexpression and inhibition 
experiments of Gtl2 lncRNA in cardiomyocytes and in the murine heart. 
Furthermore, I have established the efficacy of these expression vectors. 
However, the effectiveness of the additional Gtl2 constructs remain to be 
determined. Future directions include pursuing the use of shMEG3 for knocking 
down Gtl2 lncRNA expression levels in NRVMs. Since shMEG3 was only used 
once to knockdown Gtl2 expression levels basally (Figure 3.1.2), this experiment 
would need to be replicated several times to confirm that the knockdown is 
reproducible. Once robust knockdown of Gtl2 basal expression levels is 
confirmed, shMEG3 can be used in place of the GapmeRs for the in vitro 
hypertrophy experiments. Expression analysis of hypertrophic markers Nppa 
(ANF) and Nppb (BNP) will be performed to determine if the reduction of Gtl2 
lncRNA expression levels causes attenuation of hypertrophy. To validate the 
expression analysis, immunohistochemistry against α-actin and DAPI will be 
performed to measure cardiomyocyte surface area. Additionally, Gtl2 
overexpression experiments will be performed in NRVMs utilizing the adenovirus 
encoding for MEG3. Similar, to the knockdown experiments, expression analysis 
will be done to confirm the overexpression of MEG3 and other marker genes, 
such as those for proliferation and cell death. Immunohistochemistry will be used 
to validate the expression analysis.  
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To compliment the in vitro experiments, the rAAV9/MEG3 virus will be 
administered with intraperitoneal injection. Both mice pups and adult mice will be 
injected with the virus. The hearts will be dissected and observed for any 
phenotypic changes. If phenotypic changes are apparent, immunohistochemistry 
can be performed using cross sections of the heart tissue. Additionally, to confirm 
MEG3 overexpression as well as the dysregulation of other marker genes for 
proliferation, hypertrophy, and cell death, qRT-PCR will be performed. Similar 
knockdown in vitro experiments with rAAV9 encoding a shGtl2 will be done and 
the results will be compared. Taken together, the results from these experiments 
will aide us in developing a deeper understanding of Gtl2’s role in the heart.   
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